Test Code ADAM13 ADAMTS13 Activity and IgG Ab w/ Reflex to Inhibitor
Clinical Information
Thrombotic Thrombocytopenic Purpura (TTP) is a thrombotic microangiopathy that frequently leads to devastating thrombotic complications and sometimes death. ADAMTS13 protease deficiency is a primary risk factor in pathogenesis of TTP. An ADAMTS13 activity result of <10% can confirm a diagnosis of TTP. Anti-ADAMTS13 IgG antibodies inhibit ADAMTS13 activity. This test can be used to help differentiate between congenital and acquired TTP when coupled with an ADAMTS13 activity assay.
Synonym
- AD13A
- AD13IGG
- von Willebrand Factor Cleaving Protease
- Anti-ADAMTS13 antibodies
Profile Information
Reporting Name | Available Separately | Always Reported |
---|---|---|
ADAMTS13 Activity | No | Yes |
ADAMTS13 IgG Antibody | No | Yes |
Specimen Required
Acceptable Container/Tube: 3.2% Citrate Blue Top
Specimen Volume: 0.5 mL platelet poor plasma
Specimen Minimum Volume: 0.5 mL platelet poor plasma
Processing instructions: Do not refrigerate blood. Ensure tube is filled to the line. Within 2 hours of collection, process into platelet poor plasma. Follow CLSI Guideline H21 for processing platelet poor plasma. Transfer plasma to plastic tube. FREEZE IMMEDIATELY at -20°C or below. Ship frozen on dry ice.
Specimen Stability Information
Ambient: Whole blood must be processed into plasma and frozen within 2 hours from collection.
Frozen: 4 weeks at -20°C or below
Rejected Due To
- Clotted specimens
- Underfilled or overfilled tube
Testing Algorithm
Inhibitor titer test (LAB1006) reflexes if ADAMTS13 activity is <30% and patient has not had a high inhibitor result in the past. Once a patient has a high inhibitor result (0.5 BU or higher), inhibitor testing will no longer be performed on future samples for that patient. Patients who are confirmed to have congenital TTP will not have inhibitor titer testing performed.
Samples that reflex for inhibitor titer test will be sent to ARUP for testing at an additional charge.
Reflex Tests
Reporting Name | Available Separately | Always Reported |
---|---|---|
ADAMTS13 Inhibitor | No | No |
Reference Values
ADAMTS13 Activity
≥40 %
ADAMTS13 IgG Antibody
≤12.0 U/mL
Cautions
ADAMTS13 Activity: Mild to moderate deficiencies of ADAMTS13 of unclear clinical significance have also been observed in other clinical conditions, such as atypical hemolytic uremic syndrome (aHUS), sepsis, disseminated intravascular coagulation, and metastatic malignancy.
ADAMTS13 IgG Antibodies: Samples with high concentrations of autoantibodies other than anti-ADAMTS13 may result in weak positive or borderline results. Elevated bilirubin levels may cause a negative interference with anti-ADAMTS13 IgG antibodies test results.
Method Description
Technozym enzyme-linked immunosorbent assay (ELISA)
Performing Lab
Clinical Lab UH
Day(s) Performed
Monday through Friday (excludes OSU holidays)
Report Available
ADAMTS13 activity: 3 to 5 days
ADAMTS13 IgG antibodies: 5 to 7 days
Reporting Name
ADAMTS13 Activity
ADAMTS13 IgG Antibody
CPT Code Information
85397
83520
LOINC Code Information
53622-7
40824-5